Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 129

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 1
Chunk 129
---
 million decrease in operating expenses due primarily to lower selling and administrative costs of $7.9 million due primarily to Project Energize, as well as decreased research and development expenses, partially offset by higher restructuring costs associated with Project Energize and Nutrition Network Optimization.

CONSUMER SELF-CARE INTERNATIONAL FINANCIAL RESULTS

Three Month Comparison

 Three Months Ended(in millions, except percentages)June 28, 2025June 29, 2024Net sales$434.3 $431.3 Gross profit$200.2 $205.0 Gross profit %46.1 %47.5 %Operating income$59.2 $(10.3)Operating income %13.6 %(2.4)%

Net sales increased $3.0 million, or 0.7%, due primarily to: 

•$18.2 million increase from favorable foreign currency translation; 

•$10.9 million increase, or 2.7%, due primarily to higher net sales of $11.7 million in the Pain and Sleep-Aids categories, led by improved supply of the Solpadeine brand, as well as higher net sales of $2.6 million in the Upper Respiratory category led by restored supply of the Physiomer® brand, and $2.2 million from the Women's Health category led by strong share gains in ellaOne®, partially offset by lower net sales in the Skin Care category. These factors were partially offset by

•$26.2 million decrease due to the prior year divestitures of the Rare Diseases Business and the Hospital & Specialty Business and the sale of branded products;

46

Perrigo Company plc - Item 2CSCI

CSCI net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)June 28, 2025June 29, 2024$ Change% ChangeSkin Care$122.9 $127.7 $(4.8)(3.8)%Pain and Sleep-Aids63.5 50.3 13.2 26.2 %Healthy Lifestyle60.7 57.5 3.2 5.6 %Upper Respiratory55.4 50.7 4.7 9.3 %Women's Health41.1 36.9 4.2 11.4 %VMS38.6 39.9 (1.3)(3.